Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis

Moderate to Severe Psoriasis Clinical Trial

Official title:

A Single Arm, Open Label Study to Explore if Response to Intralesional Alefacept Injections Prior to the Standard Course of Intramuscular Treatment Can Predict Clinical Outcomes in Patients With Moderate to Severe Chronic Plaque Psoriasis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00678470
• Other study ID #: KOO-AMEVIVE-2008
• Secondary ID: CHR-H5939-31199-
• Status: Completed
• Phase: N/A
• Start date: September 2007
• Est. completion date: June 2011

Study information

• Verified date: April 2019
• Source: University of California, San Francisco
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-center, open-label, pilot study. A total of 18 subjects will be enrolled in this 6 month study to evaluate whether the response to intralesional alefacept injections prior to the standard course of intramuscularly (IM) treatment can predict clinical outcomes in psoriasis patients. One lesion with a psoriasis severity assessment score greater than 3 and an induration score greater than 1 will be identified on each patient. Each lesion will receive only one intralesional alefacept injection during the first three weeks of the study (1 lesion per week). Following a 2 week observation period, subjects will undergo a standard 12 week course of weekly intramuscular alefacept injections. The Psoriasis Area Severity Index (PASI) score will be used to determine the effectiveness of the intramuscular alefacept treatments. An 8 week follow-up period will begin after the last dose of alefacept is administered where safety and efficacy measures will continue to be monitored as outlined in the study procedures. The hypothesis is that the response to intralesional alefacept injections, whether it is positive or no benefit, will predict the clinical response to intramuscular alefacept administration.

Description:

See Brief Summary

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: June 2011
• Est. primary completion date: June 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subjects are nonimmunocompromised males or females 18 years of age or older

2. Subjects have moderate to severe plaque-type psoriasis.

3. Subjects have a Body Surface Area (BSA) involvement of greater than 5%.

4. Subjects have a Psoriasis Area and Severity Index (PASI) greater than 10.

5. Subjects have three psoriatic lesions with psoriasis severity score greater than or equal to 6 and an induration score greater than or equal to 2.

6. Subjects' target lesions are greater than 2 cm2 preferably on similar anatomical regions.

7. Subjects are eligible for systemic therapy, particularly alefacept, in the opinion of the investigator.

8. Before any study-specific procedure, subject must sign/date the appropriate written informed consent, HIPAA authorization, and a photography consent form.

9. Negative urine pregnancy test within 7 days before the first dose of alefacept in all women (except those surgically sterile or at least 1 years postmenopausal)

10. Subjects must be in general good health with no other skin disease, state of physical condition which would impair evaluation of psoriasis or which would increase their health risk by study participation.

11. Subject agrees to comply with protocol requirements, attend all regularly study visits and is considered to be a good study subject.

12. Subject meets concomitant medication washout requirements.

Exclusion Criteria:

1. Subjects with erythrodermic, pustular, or guttate psoriasis.

2. Evidence of skin conditions other than psoriasis that would interfere with study-related evaluations of psoriasis.

3. Subject has a known sensitivity to any component of the study medications.

4. Evidence of active infections such as fevers, chills, sweats, or history of untreated Lyme disease and active severe infections within 4 weeks before screening visit, or between the screening and Week 0 visits.

5. Subjects whose CD4+ T-lymphocyte count at study entry is less than the lower limit of normal per reference laboratory.

6. History of immune compromised status [e.g. human immunodeficiency virus (HIV) positive status or other immune suppressing drug] or a congenital or acquired immunodeficiency.

7. Subject has a poorly controlled medical condition including, but not limited to, unstable cardiovascular disease, poorly controlled diabetes, recent stroke, history of recurrent infections, or any other condition for which, in the opinion of the investigator, participation in the study would place the subject at risk.

8. Subject has a history of or ongoing drug or alcohol abuse.

9. Female subjects who are not postmenopausal for at least 1 year, surgically sterile, or willing to practice effective contraception during the study. Nursing mothers, pregnant women and women planning to become pregnant while on study are to be excluded.

10. Subject plans to receive any live vaccines during the study.

11. Current enrollment in another clinical study and treatment with another experimental drug or approved therapy for experimental use within 30 days prior to Week 0.

12. Subjects that cannot commit to all the assessments required by the protocol.

13. Any disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures.

14. Subject is considered by the investigator, for any reason, to be an unsuitable candidate for study participation.

15. Subjects that cannot or do not wish to comply with the protocol

Related Conditions & MeSH terms

• Moderate to Severe Psoriasis
• Psoriasis

Intervention

Drug:
• Intralesional Alefacept
Patients enrolled in this study will receive intralesional alefacept injections to a single psoriatic plaque at week 0. After a two week observation period, patients will receive 15 mg intramuscular alefacept for 12 weeks.

Locations

Country	Name	City	State
United States	UCSF Psoriasis and Skin Treatment Center	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
University of California, San Francisco

Country where clinical trial is conducted

United States, 

References & Publications (1)

Bhutani T, Kamangar F, Zitelli K, Chiang C, Gattu S, Nguyen T, Becker E, Koo J. Intralesional injections of alefacept may predict systemic response to intramuscular alefacept: results from a pilot study. J Dermatolog Treat. 2013 Oct;24(5):348-50. doi: 10. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Either or Both Intralesional Response and Systemic Response	Target plaque assessment completed using local Physician's Global Assessment score (PGA). Systemic response measured by comparing Psoriasis Area and Severity Index score at week 22 compared to baseline. Correlation measured using Fisher's non parametric test of association.	22 weeks